Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year period supported by the German Federal Ministry of Education and Research (BMBF) and […]
https://artes-biotechnology.biz/wp-content/uploads/2016/11/Artes-Biotechnology-News-1.png200200wp_art_ad-biotechhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngwp_art_ad-biotech2014-10-06 10:24:262016-11-11 09:44:11ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development
ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). The project will use exciting novel technology developed at the Burnet Institute. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the […]
https://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-box-e1478849890427.png134134wp_art_ad-biotechhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngwp_art_ad-biotech2014-07-29 10:27:202014-11-11 10:38:02Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project
ARTES Biotechnology has entered into a strategic collaboration with a subsidiary of Sun Pharmaceutical Industries Ltd, an international specialty pharmaceutical company with a diversified product portfolio headquartered in Mumbai/India. This step broadens ARTES’ international client base and demonstrates its ability to attract blue chip pharmaceutical companies. Under the collaboration agreement, ARTES will be responsible to […]
https://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-box-e1478849890427.png134134wp_art_ad-biotechhttps://artes-biotechnology.biz/wp-content/uploads/2014/11/artes-Logo1-300x137.pngwp_art_ad-biotech2014-05-15 10:28:572014-11-11 10:38:27Strategic cooperation between ARTES & Sun Pharma
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development
Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year period supported by the German Federal Ministry of Education and Research (BMBF) and […]
Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project
ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). The project will use exciting novel technology developed at the Burnet Institute. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the […]
Strategic cooperation between ARTES & Sun Pharma
ARTES Biotechnology has entered into a strategic collaboration with a subsidiary of Sun Pharmaceutical Industries Ltd, an international specialty pharmaceutical company with a diversified product portfolio headquartered in Mumbai/India. This step broadens ARTES’ international client base and demonstrates its ability to attract blue chip pharmaceutical companies. Under the collaboration agreement, ARTES will be responsible to […]